LACTOLOGY FOUNDATION

Nizatidine (ATC A02BA04) is a histamine H2‑receptor antagonist used as an antisecretory gastrointestinal agent, considered compatible with breastfeeding at usual therapeutic doses, with low expected toxicity for the breastfed infant.

Pharmacological profile

Nizatidine is a potent, selective, competitive and fully reversible histamine H2‑receptor antagonist acting on gastric parietal cells to reduce basal and stimulated gastric acid secretion. It decreases gastric acid output, gastric juice volume and hydrogen ion concentration, and also inhibits pentagastrin‑induced acid secretion.

After oral administration, bioavailability exceeds 70%, with a volume of distribution of approximately 0.8–1.5 l/kg and plasma protein binding around 35%, mainly to alpha1‑acid glycoprotein. Peak plasma concentrations are reached within about 0.5–3 hours, and the elimination half‑life is 1–2 hours, prolonged in renal impairment. Nizatidine is metabolised predominantly hepatically, while 60–80% of a dose is excreted unchanged in urine, and once‑daily evening dosing (around 18:00) may provide effective nocturnal acid suppression.

Indications and contraindications

Approved indications include short‑term treatment of active duodenal and benign gastric ulcers, treatment of erosive oesophagitis and gastro‑oesophageal reflux disease, long‑term prophylaxis of duodenal ulcer recurrence, management of gastric hypersecretory states and prophylaxis of upper gastrointestinal bleeding in critically ill patients. Nizatidine is also used for relief of heartburn and dyspepsia, and has been employed off‑label as part of multidrug regimens for Helicobacter pylori eradication.

Contraindications include hypersensitivity to nizatidine and cross‑hypersensitivity to other H2‑receptor antagonists. Caution is advised in children under 12 years because of limited safety data in this age group, and dose reductions are required in significant renal impairment.

Clinical use summary

Toxicological considerations

At therapeutic doses, nizatidine is generally well tolerated; common adverse reactions include headache, abdominal pain, nausea, vomiting, diarrhoea, flatulence, dizziness and upper respiratory symptoms such as rhinitis. Rare but clinically significant reactions described for H2‑receptor antagonists as a class include hypersensitivity reactions, hepatic enzyme elevations, cholestatic jaundice, blood dyscrasias and central nervous system effects such as confusion, especially in severely ill or elderly patients.

Because nizatidine is primarily renally excreted, accumulation can occur in moderate to severe renal impairment, enhancing the risk of adverse effects if doses are not appropriately reduced. In overdose, expected manifestations derive from exaggerated pharmacodynamic effects and non‑specific toxicity (e.g. pronounced GI symptoms, CNS disturbances), and management is supportive with attention to airway, circulation, decontamination when appropriate and renal function monitoring.

Use in pregnancy

Nizatidine is classified as pregnancy category B, indicating that animal studies have not demonstrated a teratogenic effect but adequate and well‑controlled human data are lacking. Consequently, use in pregnancy should be limited to situations where expected maternal benefit clearly outweighs potential, albeit currently unproven, fetal risk, and alternative agents with more extensive pregnancy experience may be preferred.

Use during lactation

Pharmacokinetic studies demonstrate transfer of nizatidine into human breast milk, with milk‑to‑plasma ratios ranging approximately from 1 to 4.9, indicating that milk concentrations can sometimes exceed maternal plasma levels. In one study, the average amount excreted into milk over 12 hours was about 96 micrograms, representing less than 0.1% of the maternal oral dose; overall, about 0.1% of the administered dose is recovered in human milk.

Local data from the Lactologia Foundation suggest a maternal plasma concentration around 1.59 mg/l, with an estimated infant intake via breast milk of roughly 4.8% of the maternal weight‑adjusted dose based on calculated exposure. International lactation resources (e.g. LactMed and medicines information centres) conclude that because breast‑milk levels are low and the absolute ingested dose is very small, nizatidine is not expected to cause adverse effects in breastfed infants.

The drug has a short elimination half‑life, and its low oral toxicity at these exposure levels further supports compatibility with breastfeeding, especially when therapy uses the lowest effective dose for the shortest duration. No clinically significant adverse effects in breastfed infants have been documented to date with maternal nizatidine therapy, although systematic infant monitoring remains limited.

Lactation safety classification

Within the presented framework, nizatidine is assigned toxico‑lactation category I, indicating that it is suitable for use during lactation without the need for temporary interruption of breastfeeding, as the infant dose via milk is considered very low and clinically unlikely to be harmful. Breastfeeding can therefore be continued during maternal treatment, while the infant is observed for non‑specific reactions such as changes in feeding, irritability or gastrointestinal symptoms as a prudent precaution.

Practical recommendations for clinicians

For lactating women requiring antisecretory treatment, nizatidine may be chosen when clinically indicated, with standard adult dosing adjusted for renal function and overall clinical status. In line with general principles for medicine use in breastfeeding, clinicians should use the minimal effective dose, avoid unnecessary prolonged therapy and, where feasible, schedule dosing immediately after a feed to minimise peak milk concentrations at the next feeding.

When alternative H2‑antagonists are considered, it is relevant that famotidine and nizatidine appear in breast milk in lower relative amounts than some other agents, yet all H2‑receptor antagonists are regarded as compatible with breastfeeding and none is clearly contraindicated at usual doses. In lactating patients with severe renal insufficiency or polypharmacy, additional vigilance is warranted to detect potential cumulative toxicity or pharmacodynamic interactions.